Last reviewed · How we verify
NCT04634461
The Relationship Between Panic Attack Symptoms and Atrial Fibrillation Episodes.
trial testing Cardiac Monitor in Atrial Fibrillation Paroxysmal in 13 participants. Terminated before completion.
7 April 2025
Quick facts
| Lead sponsor | State University of New York at Buffalo |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 13 |
| Start date | 15 March 2021 |
| Primary completion | 7 April 2025 |
| Estimated completion | 7 April 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cardiac Monitor
Conditions studied
- Atrial Fibrillation Paroxysmal — all drugs for Atrial Fibrillation Paroxysmal →
- Panic — all drugs for Panic →
- Panic Disorder — all drugs for Panic Disorder →
- Panic Attacks — all drugs for Panic Attacks →
Sponsor
State University of New York at Buffalo
Who can join
Adults 21 to 75, any sex, with Atrial Fibrillation Paroxysmal or Panic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To characterize the relationship between panic attack symptoms and atrial fibrillation episodes using a real-time assessment data capturing system that reduces recall biases of previous research.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04634461
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cardiac Monitor
Trials testing the same drug.
- NCT03519347 — Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A · NA · completed
Other recruiting trials for Atrial Fibrillation Paroxysmal
Currently open trials in the same condition.
- NCT06557876 — The Effect of Pulse Field Ablation on Atrial Mechanics in Catheter Ablation of Paroxysmal Atrial Fibrillation · NA · recruiting
- NCT06696170 — CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation · NA · recruiting
- NCT06172699 — Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study · active not recruiting
- NCT05549752 — Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Pati · Phase 3 · recruiting
- NCT05292209 — RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring · Phase 2 · recruiting
Other State University of New York at Buffalo trials
Trials by the same sponsor.
- NCT07072767 — Hybrid Dissemination Study of A Digital-Analog Intervention to Increase Live Donor Kidney Transplantation · NA · not yet recruiting
- NCT07140848 — CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes · NA · not yet recruiting
- NCT07433959 — Neuromodulation to Improve Grasping Function After SCI · NA · not yet recruiting
- NCT07403539 — Speech Learning and Speech Production in Parkinson's Disease · NA · recruiting
- NCT05367362 — Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute · Phase 2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04634461 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by State University of New York at Buffalo
- Last refreshed: 13 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04634461.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing